WVE Should I Buy

Wedbush analyst Yun Zhong raised the firm's price target on Wave Life Sciences to $35 from $33 and keeps an Outperform rating on the shares. After last week's Q4 update reaffirmed that all 2026 catalysts remain on track, the firm had an opportunity to discuss with management about the pathway to approval for WVE-007. According to management, statistically significant body weight reduction of equal or less than 5% vs. placebo at 12 months, based on the FDA draft guidelines on drug development for weight reduction, with improved body composition, should be sufficient to support an FDA approval. The discussion also let the firm believe that the Q1 2026 study update this month should show sustained reduction of Activin E expression and fat loss at 240mg at six months, and higher reduction in both total and visceral fat at 400mg at three months.